Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Non-cash Items (2022 - 2025)

Atara Biotherapeutics' Non-cash Items history spans 4 years, with the latest figure at $67676.0 for Q4 2025.

  • For Q4 2025, Non-cash Items rose 150.65% year-over-year to $67676.0; the TTM value through Dec 2025 reached $67676.0, up 150.65%, while the annual FY2025 figure was $67676.0, 60.78% down from the prior year.
  • Non-cash Items reached $67676.0 in Q4 2025 per ATRA's latest filing, down from $2.7 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $47.4 million in Q1 2022 to a low of $27000.0 in Q4 2024.
  • Average Non-cash Items over 4 years is $14.8 million, with a median of $5.0 million recorded in 2024.
  • The largest YoY upside for Non-cash Items was 150.65% in 2025 against a maximum downside of 98.32% in 2025.
  • A 4-year view of Non-cash Items shows it stood at $42000.0 in 2022, then surged by 74661.9% to $31.4 million in 2023, then tumbled by 99.91% to $27000.0 in 2024, then skyrocketed by 150.65% to $67676.0 in 2025.
  • Per Business Quant, the three most recent readings for ATRA's Non-cash Items are $67676.0 (Q4 2025), $2.7 million (Q3 2025), and $400000.0 (Q2 2025).